catumaxomab
Sign in to saveCatumaxomab, sold under the brand name Removab among others, is a rat-mouse hybrid monoclonal antibody which is used to treat malignant ascites, a condition occurring in people with metastasizing cancer. It binds to antigens CD3 and EpCAM. It was developed by Fresenius Biotech and Trion Pharma (Germany).
In the Vinony graph
Vinony's link graph records 344 inbound references to catumaxomab, and connects out to fusion protein, dinutuximab and Germany.
Vinony files it under Chemicals that do not have a ChemSpider ID assigned, Drugboxes which contain changes to verified fields and Drugs that are a monoclonal antibody.
Vinony links it to 6 Wikipedia language editions.
Chemical data
Drug data · ChEMBL
- Max clinical phase
- Approved
- Molecule type
- Antibody
- First approval
- 2009
- Admin. routes
- parenteral
- Indications
- neoplasm, Ascites, gastric adenocarcinoma, Fallopian Tube Carcinoma
via ChEMBL · EBI
Research
130 papers- Catumaxomab: First Approval.Drugs · 2025
- Catumaxomab: in malignant ascites.Drugs · 2012
- Catumaxomab: a bispecific trifunctional antibody.Drugs of today (Barcelona, Spain : 1998) · 2009
- Catumaxomab: clinical development and future directions.mAbs · 2010
- Catumaxomab--trifunctional anti-EpCAM antibody used to treat malignant ascites.Expert opinion on biological therapy · 2010
via PubMed
Wikidata facts
- Subclass of
- chemical compound
- Has use
- medication
Show 1 more fact
- subject has role
- monoclonal antibody
Sources (2)
via Wikidata · CC0
~3 min read
Encyclopedic overview
8 sectionsContents
- Medical use
- Adverse effects
- Mechanism of action
- Chemical structure
- History
- Society and culture
- Legal status
- References
Catumaxomab, sold under the brand name Removab among others, is a rat-mouse hybrid monoclonal antibody which is used to treat malignant ascites, a condition occurring in people with metastasizing cancer. It binds to antigens CD3 and EpCAM. It was developed by Fresenius Biotech and Trion Pharma (Germany).
== Medical use == In the European Union, catumaxomab is indicated for the intraperitoneal treatment of malignant ascites in adults with epithelial cellular adhesion molecule (EpCAM)-positive carcinomas, who are not eligible for further systemic anticancer therapy. Ascites is an accumulation of fluid in the peritoneal cavity.
Excerpted from Wikipedia’s “catumaxomab” article, available under the CC BY-SA 4.0 licence.